Abstract
Provisional patent specification filed with the United States Patent and Trademark Office (USPTO) by Glen Charles Ritschel, Ritschel Research, Tega Cay, South Carolina (Micro-Entity; Application # 64/016,256; Confirmation # 1999; Patent Center # 75002501; filed March 25, 2026). This specification discloses a computational drug repurposing method applied to bulk RNA sequencing data from ALS patient spinal cord tissue (GSE153960; Prudencio et al., 2020; 1,659 samples). Differential expression analysis identified 28,210 dysregulated genes, from which 65 ChEMBL-tractable targets were extracted spanning kinase signaling (CAMK4, MAP2K6, NRK), chromatin remodeling (RSF1, ING3, SMC3, ARID2, SMCHD1), DNA damage response (USP1, RIF1), and nuclear regulation (RORA, SP3). Screening of 12,165 unique compounds with USPTO prior art verification identified all 12,165 as NOVEL_ALL (100%). Top leads: CHEMBL5653589 (18 targets, score 189.7), MOLIBRESIB (CHEMBL1232461, BET bromodomain inhibitor, 13 targets, score 137.8), SUNITINIB (CHEMBL535, 4 targets, score 46.7). Pipeline code: https://github.com/glenritschel/als-scrna